Skip to content

S. 545 · 119th Congress (2025–2027)

Combating Illicit Xylazine Act

This bill regulates xylazine under the Controlled Substances Act (CSA).

Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.

This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.

Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.

The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.

The bill also exempts xylazine manufacturers from the CSA's physical security requirements.

Finally, the bill requires the DEA, in coordination with the Department of Health and Human Services (HHS), to provide Congress with a report on how the agencies previously determined whether xylazine should be a controlled substance, including the full text of HHS's recommendations to the DEA for scheduling xylazine.

Show official title

A bill to prohibit certain uses of xylazine, and for other purposes.

Reported

This bill’s path

This is S. 545’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Catherine Cortez Masto (D-NV)
Cosponsors
35 cosponsors

18 original · 17 later

19 R · 15 D · 1 I

  1. Sen. Richard Blumenthal (D-CT)· Original · Feb 12, 2025
  2. Sen. Katie Boyd Britt (R-AL)· Original · Feb 12, 2025
  3. Sen. Maria Cantwell (D-WA)· Original · Feb 12, 2025
  4. Sen. Shelley Moore Capito (R-WV)· Original · Feb 12, 2025
  5. Sen. Chuck Grassley (R-IA)· Original · Feb 12, 2025
  6. Sen. Kirsten E. Gillibrand (D-NY)· Original · Feb 12, 2025
  7. Sen. Margaret Wood Hassan (D-NH)· Original · Feb 12, 2025
  8. Sen. Cindy Hyde-Smith (R-MS)· Original · Feb 12, 2025
  9. Sen. Amy Klobuchar (D-MN)· Original · Feb 12, 2025
  10. Sen. Mark Kelly (D-AZ)· Original · Feb 12, 2025
  11. Sen. Tim Kaine (D-VA)· Original · Feb 12, 2025
  12. Sen. Ben Ray Luján (D-NM)· Original · Feb 12, 2025
  13. Sen. James E. Risch (R-ID)· Original · Feb 12, 2025
  14. Sen. Jacky Rosen (D-NV)· Original · Feb 12, 2025
  15. Sen. Jeanne Shaheen (D-NH)· Original · Feb 12, 2025
  16. Sen. Rick Scott (R-FL)· Original · Feb 12, 2025
  17. Sen. Roger F. Wicker (R-MS)· Original · Feb 12, 2025
  18. Sen. Todd Young (R-IN)· Original · Feb 12, 2025
  19. Sen. Ruben Gallego (D-AZ)· Later · Feb 18, 2025
  20. Sen. Thom Tillis (R-NC)· Later · Feb 24, 2025
  21. Sen. John Fetterman (D-PA)· Later · Jul 16, 2025
  22. Sen. Michael F. Bennet (D-CO)· Later · Jul 22, 2025
  23. Sen. Ted Budd (R-NC)· Later · Jul 23, 2025
  24. Sen. Cynthia M. Lummis (R-WY)· Later · Jul 23, 2025
  25. Sen. Angus S. King Jr. (I-ME)· Later · Jul 24, 2025
  26. Sen. James C. Justice (R-WV)· Later · Sep 10, 2025
  27. Sen. Mike Crapo (R-ID)· Later · Sep 29, 2025
  28. Sen. David McCormick (R-PA)· Later · Feb 10, 2026
  29. Sen. James Lankford (R-OK)· Later · Feb 24, 2026
  30. Sen. Ashley Moody (R-FL)· Later · Mar 17, 2026
  31. Sen. Marsha Blackburn (R-TN)· Later · Mar 19, 2026
  32. Sen. John Cornyn (R-TX)· Later · Mar 19, 2026
  33. Sen. Ted Cruz (R-TX)· Later · Mar 26, 2026
  34. Sen. Richard J. Durbin (D-IL)· Later · Mar 26, 2026
  35. Sen. Jeff Merkley (D-OR)· Later · Jun 9, 2026
Policy area
Crime and Law Enforcement
Subjects
  • Congressional oversight
  • Consumer affairs
  • Criminal procedure and sentencing
  • Drug safety, medical device, and laboratory regulation
  • Drug trafficking and controlled substances
  • Licensing and registrations
  • Manufacturing
  • U.S. Sentencing Commission
  • 1 more
    • Veterinary medicine and animal diseases

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Feb 12, 2025 – Apr 15, 2026
    1. Referred to committee

      Read twice and referred to the Committee on the Judiciary.

      Sources
    2. Ordered reported

      Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

      Sources
    3. Reported by committee

      Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

      Sources

Committees

  1. SenateJudiciaryReferred Feb 12, 2025 · Markup Mar 26, 2026
    1. Mar 26, 2026 · Meeting

    2. Mar 19, 2026 · Meeting

    3. Mar 12, 2026 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (2)
  1. Combating Illicit Xylazine Act

    Display title, Short title · Reported to Senate, Introduced in Senate

  2. A bill to prohibit certain uses of xylazine, and for other purposes.

    Official title · Introduced in Senate